0 Promising results for Phase I live-attenuated Ebola vaccine
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Browsing: Clinical > Vaccines
0 ASM Microbe: NS1-based Zika vaccine demonstrates promise in mice
Research presented at ASM Microbe has reported a Zika vaccine based on the NS1 protein can induce protective immunity in mouse models after a single dose.
0 Development and delivery of a peptide-based vaccine against group A Streptococcus
In this exclusive piece the authors discuss the choice of peptide antigen, delivery system/adjuvant and delivery route as key factors in the development of an effective human vaccine against group A Streptococcus.
0 Adoption of the HPV vaccine: a case study of three emerging countries
The human papillomavirus (HPV) vaccine has recently attracted considerable attention in emerging countries. In this research article, the authors carry out a multi-country case study investigating the the adoption and use of HPV vaccines.
0 Structure uncovered for Lassa virus glycoprotein
Researchers have uncovered structural and functional details of a key Lassa virus protein; this new information may aid the development of vaccines and therapeutics in the future.
0 Structure of clade C HIV-1 envelope glycoprotein determined
A team from the Scripps Research Institute have determined the structure of clade C HIV-1 envelope glycoprotein, an immunogen that could be utilized in a future HIV vaccine.
0 IDHTalks with Helen McShane: Developing a new tuberculosis vaccine
Helen McShane discusses her work leading the TB vaccine research program at Oxford University, and shares her thoughts on the challenges facing vaccine development and eradication of this disease.
0 Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice
Development of protein vaccine to prevent congenital infection is a public health priority, this research investigates the design of a mucosal synthetic pathogen as a vaccine strategy against congenital toxoplasmosis.
0 Host–virus interactions in hepatitis – an interview with Marcus Dorner
In line with Hepatitis Awareness Month, we spoke to Marcus Dorner about his current research into the host–virus interactions in hepatitis B and C infection, their implications for vaccine development and more.
0 Varicella zoster virus tissue tropism – a target in vaccine development
In this exclusive opinion piece, the authors discuss how a neuroattenuated varicella zoster virus (VZV) vaccine could provide promising protection against VZV infection.